Last deal

$105M

Amount

Post-IPO Equity

Stage

24.05.2022

Date

3

all rounds

$276M

Total amount

date founded

Financing round

General

About Company
Chinook Therapeutics is a biotechnology company specializing in developing precision medicines for kidney diseases.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2019

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

Founded in 2019 and headquartered in Alberta, Canada, Chinook Therapeutics is a clinical-stage biopharmaceutical company focused on addressing the lack of effective treatments for kidney diseases. Utilizing innovative translational platforms and patient stratification tools, the company aims to discover and develop therapeutics for rare, severe chronic kidney disorders. With the acquisition by Novartis in August 2023, Chinook Therapeutics has positioned itself as a key player in the field, offering potential solutions to the global problem of kidney diseases and their associated high costs to healthcare systems.
Similar Companies
1000
Elgia Therapeutics

Elgia Therapeutics

Elgia Therapeutics develops innovative medicines for chronic inflammatory and fibrotic diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

San Diego, CA, USA

total rounds

2

total raised

$2.33M
VRG Therapeutics

VRG Therapeutics

VRG Therapeutics develops miniprotein-based meds and gene therapy to cure untreatable diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Budapest, Hungary

total rounds

1

total raised

$5.48M
Amicus Therapeutics

Amicus Therapeutics

Amicus Therapeutics is a biotechnology company focused on developing and delivering treatments for rare metabolic diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cranbury, NJ, USA

total rounds

20

total raised

$2.42B
Digestome Therapeutics

Digestome Therapeutics

Digestome Therapeutics is a biotechnology company focused on developing drugs for psychiatric and inflammatory diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

total rounds

1

total raised

$10M
M&A Details
1

Transaction name

Acquired by

Novartis

announced date

12.06.2023

price

$3.5B

Financials

Funding Rounds
4
3

Number of Funding Rounds

$276M

Money Raised

Their latest funding was raised on 24.05.2022. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
24.05.2022
$105M
09.11.2021
18.08.2020
11
$106M
Co-Investors
Investors
13
1

Number of lead investors

13

Number of investors

Investor 
Lead 
Round 
Partners 
No
Post-IPO Equity
No
Post-IPO Equity
No
Post-IPO Equity
Surveyor Capital

Surveyor Capital

Surveyor Capital is an investment firm that increases access and opportunity for companies and entrepreneurs.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services

Location

Chicago, IL, USA

count Of Investments

124

count Of Exists

3
EcoR1 Capital

EcoR1 Capital

EcoR1 Capital is a biotech-focused investment advisory firm based in San Francisco.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

San Francisco, CA, USA

count Of Investments

94

count Of Exists

7
Rock Springs Capital

Rock Springs Capital

Rock Springs Capital is a Baltimore-based hedge fund that specializes in investing in late stage life science companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Life Science, Financial Services, Venture Capital

Location

Baltimore, MD, USA

count Of Investments

124

count Of Exists

16
Acquisitions
1
Acquiree Name 
Date 
Price 
Acquisition Name 
Aduro BioTech acquired by Chinook Therapeutics

Aduro BioTech acquired by Chinook Therapeutics

acquirer

Chinook Therapeutics
Chinook Therapeutics

date

02.06.2020
Aduro BioTech

Aduro BioTech

Aduro BioTech develops and sells therapies that use the body's immune system to treat diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Biopharma

Location

Berkeley, CA, USA

total rounds

12

total raised

$359.66M

People

Founders
1
Ross Haghighat
Ross Haghighat

Ross Haghighat

Ross Haghighat is a serial entrepreneur with nearly 25 years of experience in founding and transforming companies in the high tech fields of telecommunications, military electronics, biotechnology, and specialty materials. He is the founding CEO of Triton Systems, headquartered in Chelmsford, Massachusetts. Haghighat serves on the Board of Directors of Triton Systems, S12 Technologies and FRX Polymers. Haghighat co-founded Coretek, Inc., a photonic-based telecom device company that was acquired by a Fortune 100 company in a billion dollar plus deal in 2001. Haghighat holds a Bachelor of Science and Master of Science in Advanced Materials from Rutgers University and M.B.A from the Carroll School of Management at Boston College.

current job

Triton Systems
Triton Systems

count Of Investments

1

Ross Haghighat

Employee Profiles
6
Delphine Imbert

Delphine Imbert

SVP, CMC & Tech Ops

Tom Swallow

Tom Swallow

Vice President - Finance

Valerie Fauvelle

Valerie Fauvelle

VP Regulatory Affairs

Sam Hall

Sam Hall

Director

Eric Dobmeier

Eric Dobmeier

President & CEO

Ross Haghighat

Ross Haghighat

Co-founder

Activity

Recent News
7
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month